vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $13.8M, roughly 1.7× Gossamer Bio, Inc.). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -342.3%, a 383.7% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
CBK vs GOSS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $13.8M |
| Net Profit | $9.5M | $-47.2M |
| Gross Margin | — | — |
| Operating Margin | — | -333.6% |
| Net Margin | 41.3% | -342.3% |
| Revenue YoY | — | 47.1% |
| Net Profit YoY | 9.7% | -43.0% |
| EPS (diluted) | $0.69 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $13.8M | ||
| Q3 25 | $22.8M | $13.3M | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-47.2M | ||
| Q3 25 | $9.5M | $-48.2M | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | — | $-41.9M | ||
| Q3 23 | — | $-40.0M | ||
| Q2 23 | — | $-42.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | -333.6% | ||
| Q3 25 | 53.8% | -369.4% | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -342.3% | ||
| Q3 25 | 41.4% | -362.7% | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.21 | ||
| Q3 25 | $0.77 | $-0.21 | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | — | $-0.19 | ||
| Q3 23 | — | $-0.21 | ||
| Q2 23 | — | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $136.9M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $-122.8M |
| Total Assets | $2.3B | $172.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $136.9M | ||
| Q3 25 | $154.8M | $180.2M | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q3 23 | — | $328.9M | ||
| Q2 23 | — | $162.1M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-122.8M | ||
| Q3 25 | $245.2M | $-82.3M | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M | ||
| Q3 23 | — | $104.6M | ||
| Q2 23 | — | $-62.8M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $172.2M | ||
| Q3 25 | $2.2B | $208.8M | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | — | $259.4M | ||
| Q3 23 | — | $347.9M | ||
| Q2 23 | — | $181.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-48.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-48.3M | ||
| Q3 25 | $28.0M | $-36.2M | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M | ||
| Q3 23 | — | $-34.5M | ||
| Q2 23 | — | $-38.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | 6.7% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
GOSS
Segment breakdown not available.
